ngshrd | 906

HRD Assay

Keywords

BRCA1, BRCA2, BRCAness, Genomic Instability Score, GIS, Homologous Recombination Deficiency, HRD, HRR, MyChoice, Myriad, Next-Generation Sequenzierung, Next Generation Sequencing, Ovarian cancer, Ovarian carcinoma

Material

Tissue biopsy
Tube sterile, white (32)

Note

Mutations in >50 genes associated with BRCAness (incl. BRCA1, BRCA2, PALB2) and evaluation of the Genomic Instability Score (GIS)(TruSight Oncology 500 HRD powered by Myriad) To order this analysis, please contact us via contact@viollier.ch or 0848 121 121. This analysis may result in excess information. This will be communicated, unless it is noted otherwise when placing the order. Since in rare cases there may also be indications of hereditary changes, the GUMG shall arrange for the patient to be informed accordingly (see www.viollier.ch/en/SGMG_consent). Tarification: according to Tardoc

Duration

14 days

Frequency

1 x per week

Method

Next Generation Sequencing

Price

CHF 0.00

Tariff

0.00 TP

Team of consultants

MD Katharina Marston FMH Pathology, molecular pathology	FMH Pathology, molecular pathology	T +41 61 486 10 34
DSc Henriette Kurth FAMH Specialist in laboratory medicine, medical genetics	FAMH Specialist in laboratory medicine, medical genetics	T +41 61 486 14 78
MD Jean-François Egger FMH pathology	FMH pathology	T +41 22 789 63 63
PhD Christoph Noppen FAMH Specialist in laboratory medicine, medical genetics	FAMH Specialist in laboratory medicine, medical genetics	T +41 61 486 14 79
MD Santiago Giménez de Mestral FMH pathology, cytopathology	FMH pathology, cytopathology	T +41 22 789 63 36